Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biomed ; 92(S5): e2021405, 2021 09 10.
Article in English | MEDLINE | ID: mdl-34505844

ABSTRACT

BACKGROUND AND AIM: Intraabdominal hemorrhage secondary to liver and kidney injury is a major cause of morbidity and mortality. Endovascular arterial embolization is an established interventional radiology technique used to treat active bleeding, and its role in managing abdominal hemorrhages is growing, given the increasing trend for conservative treatment. Our study aims to retrospectively evaluate the technical and clinical results and the possible complications of arterial embolization procedures performed in emergency, in post-traumatic, iatrogenic, and pathological hepatic and renal bleedings. METHODS: We performed a ten-year, single-center retrospective survey (from January 2010 to December 2019) of all patients treated in emergency by intra-arterial embolization of liver and kidney bleeding. Preliminary CT angiography studies were evaluated, as well as the angiographic findings. Materials used, procedural data, and clinical outcomes, including complications, were recorded. RESULTS: The diagnostic angiography showed a single source of bleeding in 20 cases (66.7%), two bleeding vessels in 4 cases (13.3%), and multiple hemorrhagic sources in 6 cases (20%). All bleeding sources were successfully embolized; in 12 patients (40%), complete embolization was achieved with coils and 18 patients (60%) with hemostatic sponges. In one case, a second embolization procedure was performed for the persistence of hemodynamic instability. No major post-procedural complications were recorded. The mean procedure duration was 65.1 minutes. CONCLUSIONS: Based on our experience and literature data, the treatment of endovascular embolization in acute abdominal bleeding of hepatic and renal origin represents the treatment of choice, as it can provide complete therapeutic success in hemodynamically stable patients. (www.actabiomedica.it).


Subject(s)
Embolization, Therapeutic , Radiology, Interventional , Hemorrhage/diagnostic imaging , Hemorrhage/etiology , Hemorrhage/therapy , Humans , Liver , Retrospective Studies , Treatment Outcome
2.
Radiol Med ; 124(1): 34-49, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30191448

ABSTRACT

Interventional radiology provides local management of bone metastases (BM) with a palliative intent in most cases, or with a curative intent in selected patients. Its role has rapidly expanded in the last decade, offering new treatment solutions often in combination with surgery, radiation therapy and medical treatments. The aim of the present paper is to increase awareness, acceptance and adoption of interventional radiology procedures for the treatment of BM; and to present the joint position of the Italian College of Musculoskeletal Radiology and the Italian College of Interventional Radiology.


Subject(s)
Bone Neoplasms/secondary , Bone Neoplasms/therapy , Radiology, Interventional/standards , Humans , Italy
3.
Oncotarget ; 9(61): 31861-31876, 2018 Aug 07.
Article in English | MEDLINE | ID: mdl-30159128

ABSTRACT

BACKGROUND: Gemcitabine/nab-paclitaxel and FOLFIRINOX demonstrated significantly increased survival compared with gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): objective response rate (ORR) 23 and 31.6%, progression-free survival (PFS) 5.5 and 6.4 months, overall survival (OS) 8.7 and 11.1 months. Present phase II study evaluated recommended first-line triplet FIr/FOx schedule. METHODS: Simon two-step design: p010%, p130%, power 80%, α5%, ß20%. Projected ORR: I step, 1/10; II 5/29. Schedule: 12h-timed-flat-infusion/5-fluorouracil 750-800-900 mg/m2 d1-2,8-9,15-16,22-23; irinotecan 120-140-160 mg/m2 d1,15; oxaliplatin 70-80 mg/m2 d8,22; every 4 weeks, according to clinical parameters (age, comorbidities, performance status (PS), liver function). Activity and efficacy were evaluated, and compared using log-rank; limiting toxicity syndromes (LTS), using chi-square. RESULTS: Twenty-nine consecutive patients were enrolled, according to primary/intermediate/secondary Cumulative Illness Rating Scale (CIRS). Median age 62; elderly 13 (44.7%); PS2 3 (10.4%), secondary CIRS 5 (17.2%). Primary endpoint was met: ORR 53% (7/13 patients) as-treated, 50% intent-to-treat. Cumulative G3-4 toxicities: diarrhea 17%, asthenia 14%, hypertransaminasemy 7%, mucositis 7%, vomiting 3%, anemia 3%, thrombocytopenia 3%. LTS were 27.5% overall, 38.4% in elderly. At 3 months median follow-up, PFS 4 months, OS 11 months. PS2 patients showed significantly worse OS (P 0.022). CONCLUSION: Intensive first-line triplet FIr/FOx is tolerable at modulated doses, and confirms high activity/efficacy in metastatic PDAC. Patients' careful selection, and exclusion of PS2, can maintain safety profile and efficient dose intensity.

4.
Andrologia ; 50(10): e13118, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30043529

ABSTRACT

Varicocele repair (VR) is associated with improved sperm parameters in subfertile patients. We examined the association of the levels of reproductive hormones, scrotal colour Doppler ultrasound (CDU) and seminal parameters in subfertile men, before and after VR. Fifty subfertile males, with left-side varicocele, were enrolled in this retrospective study. The serum levels of FSH, LH and total testosterone (TT), along with continuous left spermatic venous reflux (SVR) and testicular volumes at CDU were evaluated, before and six months after VR by a left-side retrograde internal spermatic vein sclero-embolisation (SVE). Left-side SVR was either no longer present or significantly reduced in all patients after VR (p < 0.0001). Sperm parameters, in particular, the total sperm motile count (TMC), were found significantly improved after VR (p < 0.0001). Post-VR, no differences were observed in the baseline values of the reproductive hormones. Only SVR change was seen to predict TMC change (p = 0.026) in the univariate analysis, while reproductive hormones change had no effect on TMC change (FSH:p = 0.85;LH:p = 0.44;TT:p = 0.76). In conclusion, the improved sperm parameters were associated with the disappearance or reduction in SVR and not with changes in the levels of reproductive hormones after SVE. Thus, SVR change at CDU was the only predictor of improved sperm quality after VR in subfertile males.


Subject(s)
Embolization, Therapeutic/methods , Infertility, Male/blood , Sclerotherapy/methods , Scrotum/blood supply , Varicocele/therapy , Adult , Follicle Stimulating Hormone/blood , Humans , Infertility, Male/etiology , Infertility, Male/physiopathology , Infertility, Male/prevention & control , Luteinizing Hormone/blood , Male , Retrospective Studies , Scrotum/diagnostic imaging , Sperm Count , Sperm Motility , Spermatozoa , Testosterone/blood , Treatment Outcome , Ultrasonography, Doppler, Color , Varicocele/complications , Varicocele/diagnostic imaging , Varicose Veins/diagnostic imaging , Varicose Veins/physiopathology
5.
Interv Neuroradiol ; 24(4): 379-382, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29781370

ABSTRACT

Endovascular approach represents today the first option in treatment of ruptured and unruptured cerebral aneurysms. Nevertheless, wide-neck bifurcation aneurysms still represent a technical challenge for endovascular treatment due to the need to protect vessels arising next to the aneurysmal neck. A variety of devices have been implemented to ensure adequate assistance for coiling of these lesions. Among these devices, the new pCONus 2 represents an evolution of the well-known pCONus; compared to the previous one in fact, it allows a degree of articulation and flexibility between the shaft and the distal part (crown), making it more suitable for treatment of aneurysms presenting an angle between the longitudinal axis of the dome and parent vessel. We report our first case using pCONus 2 in the re-treatment of an unruptured anterior communicating artery aneurysm in a 57-year-old man, showing evident recanalization two years after coiling.


Subject(s)
Embolization, Therapeutic/instrumentation , Intracranial Aneurysm/therapy , Stents , Cerebral Angiography , Humans , Intracranial Aneurysm/diagnostic imaging , Male , Middle Aged , Retreatment
6.
Gland Surg ; 7(2): 132-146, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29770309

ABSTRACT

Thyroid nodules are a common incidental finding during a routinely ultrasound (US) exam unrelated to the thyroid gland in the healthy adult population with a prevalence of 20-76%. As treated before with surgery, in the last years new minimally invasive techniques have been developed as an alternative to surgery. The aim of this review, based on newly revised guidelines, is to provide some information regarding the basic principles, indications, materials, techniques, and results of mini-invasive procedures or treatments for thyroid nodules. We performed a narrative review including both newest and representative papers and guidelines based on the different procedures of ablation techniques developed in the last years for the diagnosis and the treatment of thyroid nodules. All examined papers referred very good results in term of volume nodule reduction, improvement in related symptoms and cosmetic problems, with a very low rate of complications and side effects for all the minimally invasive technique analyzed. Obviously, some differents between technique based on different kind of thyroid nodules and different indication were found. In conclusion, many thyroid nodules nowadays could be treated thanks to the advent of new mini-invasive technique that are less expensive and present a lower risk of major complications and side effects compared to surgery.

7.
J Radiol Case Rep ; 12(5): 12-18, 2018 May.
Article in English | MEDLINE | ID: mdl-30651909

ABSTRACT

Pancreatic pseudoaneurysms represent relatively rare but potentially lethal complications of acute or chronic pancreatitis, involving several visceral arteries. Due to their intrinsic instability and subsequent high risk of massive bleeding, these lesions require prompt treatment, regardless of the size of the pseudoaneurysm. First option of treatment is today represented by transcatheter embolization; this treatment, in fact, shows higher rates of clinical and technical success and lower recurrence rates than conventional surgery. We present a clinical case of endovascular management of a large pseudoaneurysm, measuring 54 × 53 mm (AP × LL), involving right gastric artery in a 35-year-old woman with history of chronic alcoholic abuse presenting with severe anemia.


Subject(s)
Aneurysm, False/diagnostic imaging , Aneurysm, False/surgery , Arteries/diagnostic imaging , Embolization, Therapeutic , Endovascular Procedures , Hemorrhage/diagnostic imaging , Hemorrhage/surgery , Pancreas/blood supply , Adult , Alcoholism/complications , Aneurysm, False/etiology , Angiography/methods , Arteries/surgery , Chronic Disease , Computed Tomography Angiography , Contrast Media , Diagnosis, Differential , Female , Hemorrhage/etiology , Humans , Pancreas/diagnostic imaging , Pancreas/surgery , Pancreatitis/complications , Pancreatitis/diagnostic imaging , Treatment Outcome , Ultrasonography
9.
Biomed Res Int ; 2014: 806391, 2014.
Article in English | MEDLINE | ID: mdl-24900987

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) patients require different treatment strategies according to disease extension, liver function, and patient's fitness. We evaluated HCC multidisciplinary management in clinical practice. METHODS: Consecutive patients were followed and treated with tailored medical, locoregional, and surgical treatments, according to disease stage and patient's fitness (age, Cumulative Illness Rating Scale (CIRS)). Activity, efficacy, and safety were evaluated. RESULTS: Thirty-eight patients were evaluated: median age, 74; elderly 92%; CIRS secondary 28 (74%); Child-Pugh A 20 (53%), B 11 (29%); and Barcelona Clinic Liver Cancer (BCLC) 0 2 (5%), A 9 (24%), B 10 (26%), C 13 (34%), and D 4 (11%). Overall survival (OS) was 30 months. At 9 months median follow-up, among 25 unresectable HCC, OS was 10 months; BCLC B-D unfit for sorafenib showed OS 3 months. Ten patients (40%) received sorafenib: Child-Pugh A 5 (50%) and B 5 (50%) and disease control rate 89%, progression-free survival 7 months, and OS 9 months. G3-4 toxicities: anorexia, hypertransaminaemia, hyperbilirubinemia, and hypercreatininemia. Limiting toxicity syndromes were 40%, all multiple sites. CONCLUSION: HCC patients require multidisciplinary clinical management to properly select tailored treatments according to disease stage, fitness, and liver function. Patients suitable for sorafenib should be carefully selected, monitored for individual safety, and prevalently characterized by limiting toxicity syndromes multiple sites.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/therapy , Disease-Free Survival , Female , Humans , Liver Neoplasms/therapy , Male , Middle Aged , Niacinamide/analogs & derivatives , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Severity of Illness Index , Sorafenib
SELECTION OF CITATIONS
SEARCH DETAIL
...